BiotechTube

[6,6-2H2]glucose

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glycogen Storage Disease Type IA

Conditions

Glycogen Storage Disease Type IA

Trial Timeline

Jan 19, 2021 → Feb 7, 2022

NCT ID
NCT04311307

About [6,6-2H2]glucose

[6,6-2H2]glucose is a phase 1/2 stage product being developed by Ultragenyx Pharmaceutical for Glycogen Storage Disease Type IA. The current trial status is completed. This product is registered under clinical trial identifier NCT04311307. Target conditions include Glycogen Storage Disease Type IA.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04311307Phase 1/2Completed

Competing Products

20 competing products in Glycogen Storage Disease Type IA

See all competitors
ProductCompanyStageHype Score
alglucosidase alfaSanofiPre-clinical
22
avalglucosidase alfaSanofiPhase 3
76
MyozymeSanofiPhase 2/3
64
MyozymeSanofiPre-clinical
22
Avalglucosidase AlfaSanofiPhase 2
51
MyozymeSanofiPhase 2/3
64
ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
84
Avalglucosidase alfa (GZ402666)SanofiApproved
84
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
76
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 2
51
Alglucosidase alfaSanofiPhase 2
51
Avalglucosidase alfaSanofiApproved
84
MyozymeSanofiPhase 1/2
40
Alglucosidase alfa GZ419829SanofiPre-clinical
22
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])SanofiPre-clinical
22
alglucosidase alfaSanofiPre-clinical
22
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
74
BEAM-301: Single dose of BEAM-301 administered by IVBeam TherapeuticsPhase 1/2
36
Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3
72
UX053 + Antipyretic + H2 Blocker + H1 BlockerUltragenyx PharmaceuticalPhase 1/2
36

Other Products from Ultragenyx Pharmaceutical

Crysvita (burosumab-twza) TreatmentApproved
80
GTX-102Phase 3
72
EvinacumabPhase 3
72
Adjuvant Immunomodulatory (IM) TherapyPhase 3
72
Oral prednisolone + Placebo for oral prednisolonePhase 3
72